1. Home
  2. DSGN vs SHMD Comparison

DSGN vs SHMD Comparison

Compare DSGN & SHMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSGN
  • SHMD
  • Stock Information
  • Founded
  • DSGN 2017
  • SHMD 1864
  • Country
  • DSGN United States
  • SHMD Germany
  • Employees
  • DSGN N/A
  • SHMD N/A
  • Industry
  • DSGN Biotechnology: Pharmaceutical Preparations
  • SHMD
  • Sector
  • DSGN Health Care
  • SHMD
  • Exchange
  • DSGN Nasdaq
  • SHMD Nasdaq
  • Market Cap
  • DSGN 208.9M
  • SHMD 179.1M
  • IPO Year
  • DSGN 2021
  • SHMD N/A
  • Fundamental
  • Price
  • DSGN $6.24
  • SHMD $4.83
  • Analyst Decision
  • DSGN
  • SHMD
  • Analyst Count
  • DSGN 0
  • SHMD 0
  • Target Price
  • DSGN N/A
  • SHMD N/A
  • AVG Volume (30 Days)
  • DSGN 196.1K
  • SHMD 614.1K
  • Earning Date
  • DSGN 11-07-2025
  • SHMD 01-01-0001
  • Dividend Yield
  • DSGN N/A
  • SHMD N/A
  • EPS Growth
  • DSGN N/A
  • SHMD N/A
  • EPS
  • DSGN N/A
  • SHMD N/A
  • Revenue
  • DSGN N/A
  • SHMD $85,165,542.00
  • Revenue This Year
  • DSGN N/A
  • SHMD N/A
  • Revenue Next Year
  • DSGN N/A
  • SHMD N/A
  • P/E Ratio
  • DSGN N/A
  • SHMD N/A
  • Revenue Growth
  • DSGN N/A
  • SHMD N/A
  • 52 Week Low
  • DSGN $2.60
  • SHMD $1.86
  • 52 Week High
  • DSGN $7.77
  • SHMD $5.28
  • Technical
  • Relative Strength Index (RSI)
  • DSGN 49.22
  • SHMD 68.19
  • Support Level
  • DSGN $6.25
  • SHMD $3.87
  • Resistance Level
  • DSGN $6.77
  • SHMD $5.28
  • Average True Range (ATR)
  • DSGN 0.48
  • SHMD 0.60
  • MACD
  • DSGN 0.02
  • SHMD 0.08
  • Stochastic Oscillator
  • DSGN 49.74
  • SHMD 75.14

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

About SHMD SCHMID Group N.V. Class A Ordinary Shares

Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

Share on Social Networks: